Understand the source comparison
AOD-9604 Side Effects Comparison — Clinical vs Anecdotal Data
Injection site erythema/swelling 5–8% of subjects Mild. No intervention required Not observed with HGH (different administration route) 24–48 hours Nausea or reduced appetite 3–5% of subjects Mild. Transient, self-limiting Not a primary HGH side effect 48–72 h
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Injection site erythema/swelling
- 5–8% of subjects
- Mild. No intervention required
- Not observed with HGH (different administration route)
- 24–48 hours
- Nausea or reduced appetite
- 3–5% of subjects
- Mild. Transient, self-limiting
- Not a primary HGH side effect
- 48–72 hours
- Headache
- 2–4% of subjects
- Mild. Resolved without analgesics
- Rare with HGH at therapeutic doses
- 12–24 hours
- Hyperglycemia or insulin resistance
- 0%. No cases reported
- Not applicable
- Common with chronic HGH use (15–25% incidence)
- Joint pain or carpal tunnel symptoms
- Common with HGH (10–20% incidence at >4 IU/day)
- Professional Assessment
- AOD-9604 demonstrates a substantially cleaner safety profile than full-length growth hormone due to its lack of GH receptor binding. The adverse events that do occur are mild, transient, and unrelated to the peptide's metabolic mechanism. They're injection technique artifacts or individual sensitivities.
- The table underscores the critical distinction: the side effects researchers fear with growth hormone simply don't occur with AOD-9604 because the receptor mechanism is absent. Chronic HGH administration carries a 15–25% risk of insulin resistance requiring dose reduction or discontinuation. AOD-9604 trials reported zero cases of glucose dysregulation across 12-week protocols. This isn't a minor difference. It's the reason AOD-9604 remains viable for long-term metabolic research where HGH would require cycle breaks to manage side effects.